EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. for potential securities fraud violations following the company's decision to end a Phase 2 trial for a prostate cancer treatment.
November 05, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ESSA Pharma Inc. is under investigation by Levi & Korsinsky for potential securities fraud after halting a Phase 2 trial for a prostate cancer treatment.
The investigation into potential securities fraud and the halting of a significant clinical trial are likely to negatively impact investor confidence and the stock price of ESSA Pharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100